DeCure's autonomous Metabolic AI scientist is researching a drug-repurposing hypothesis for non-functioning pituitary adenoma — screening already-approved drugs against its 18-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleNon-functioning pituitary adenoma maps to a 18-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for non-functioning pituitary adenoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
tripartite motif containing 24 (TRIM24) — TRIM24 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet benzyloxydrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4YBM · 1.46 Å · ligand N-{6-[3-(benzyloxy)phenoxy]-1,3-dimethyl-2-oxo-2,3-dihydro-1H-benzimidazol-5-yl}-3,4-dimethoxybenzenesulfonamide (4BJ). Experimental structure, not a prediction.
What the evidence adds up to
Surgery is the standard of care for symptomatic nonfunctioning pituitary adenomas. A 2017 retrospective series of 411 patients treated with endonasal transsphenoidal resection reports long-term outcomes from a single tertiary centre, but the abstract gives no specific rates for tumour control, recurrence, or complications. The 2010 review notes that macroadenomas often present with mass effect and that medical management advances are discussed, but it does not name any drug or provide response data for nonfunctioning adenomas. A 2012 review states that new medications have shown “certain effectiveness” in reducing tumour size and improving symptoms, but again no drug names, no response rates, and no sample sizes are given.
No abstract in this set reports a controlled trial, a survival statistic, or a numeric outcome for any medical treatment of nonfunctioning pituitary adenoma. The 2024 abstract confirms that there are no established clinical predictors of postoperative outcomes and calls for a well-annotated consecutive cohort. The 2010 and 2012 reviews mention medical alternatives but do not specify which agents were tested or how many patients responded.
What is missing is any randomised trial of a drug for nonfunctioning pituitary adenoma, any published response rate or progression-free survival figure, and any validated biomarker to stratify patients who might benefit from medical therapy rather than surgery. Without these, the role of drug treatment in this disease remains undefined.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Current Opinion in Oncology · 2010 · 26 citations
Diagnosis and management of pituitary adenomas
AbstractPURPOSE OF REVIEW: Pituitary adenomas are frequently encountered in practice either because of clinical symptoms or as incidental findings. These tumors may alter pituitary function and can therefore have a considerable impact on morbidity, mortality, and quality of life. RECENT FINDINGS: The presentation is variable for each type of tumor, with microadenomas being either silent or manifesting with symptoms of hormonal excess. In contrast, macroadenomas may present with mass effect. The various histologic types include prolactinomas, nonfunctioning adenomas, somatotropinomas, corticotropinomas, and thyrotropinomas. The present article will serve as an update on the diagnosis and treatment of pituitary adenomas. Advances in medical management for each tumor are discussed, highlighting new therapeutic alternatives. The role of surgery is also reviewed. Recommendations on the surveillance and postoperative monitoring of patients are emphasized. SUMMARY: Newer methods in the diagnosis and treatment for pituitary adenomas greatly expand our ability to care for affected patients.
European Journal of Endocrinology · 2017 · 25 citations · open access
MANAGEMENT OF ENDOCRINE DISEASE: Present and future perspectives for medical therapy of nonfunctioning pituitary adenomas
AbstractIn contrast to the clear indication for surgical treatment in symptomatic patients with clinically nonfunctioning pituitary adenomas (NFPA), there are no randomized controlled studies comparing therapeutic strategies such as watchful waiting, irradiation or medical therapy for the management of NFPA after surgery. Further, no medical therapy is currently approved for the treatment of NFPA. In this review, we summarize accumulating data on medications currently approved for secreting pituitary adenomas, used off-label in patients with NFPA. Perspectives on overall treatment optimization and potential future therapies are also detailed.
Advances in medical treatment of clinically nonfunctioning pituitary adenomas.
AbstractClinically nonfunctioning pituitary adenomas are the most common types among pituitary adenomas. These tumors are usually diagnosed in their later stages due to the absence of clinical symptoms and detectable hormonal hypersecretion. Although these tumors are benign, they are hard to be completely removed during neurosurgery due to the massive invasion into the surrounding tissues at diagnosis. Furthermore, relapse is common. In recent years, medical treatment of pituitary adenomas has witnessed a rapid development. New medications have shown certain effectiveness in reducing the tumor size and improving the clinical symptoms.
Journal of Neurological Surgery Part B Skull Base · 2017 · 0 citations
Endonasal Transsphenoidal Resection of Nonfunctioning Pituitary Adenomas: A Retrospective Single Center Series of 411 Patients
AbstractBackground/Objective: Surgical resection is widely accepted as the standard of care for treating symptomatic nonfunctional pituitary adenomas (NFPAs), typically via a transsphenoidal approach. This study evaluated long term surgical outcomes following resection of NFPAs at a major tertiary academic pituitary center.
Journal of Neurological Surgery Part B Skull Base · 2024 · 0 citations
Clinical Landscape of Pituitary Adenoma
AbstractBackground: Pituitary adenomas are common neoplasms of the sellar region, occurring in up to 25% of the population. While most are asymptomatic, they can lead to visual decline and endocrinopathies which often necessitate surgical resection. Importantly, there is lack of established clinical predictors of relevant postoperative outcomes for these patients and there is a need for a robust, consecutively treated cohort with detailed clinical annotation for further exploration.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
